American Society of Hirudotherapy

Periprocedural bridging anticoagulation: current perspectives

Review published in American journal of therapeutics (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical LiteraturePalaniswamy et al. · American journal of therapeutics, 2011

Abstract

Perioperative management of patients on chronic anticoagulant use involves balancing individual risk for thromboembolism and bleeding. Discontinuation of antithrombotic therapy can place patients at increased risk of thromboembolic complications, whereas continuing antithrombotic therapy can increase procedure-related bleeding risk. Temporary perioperative substitution of low-molecular weight heparin or unfractionated heparin in place of warfarin, "the bridge therapy" is often used in the periprocedural period, but the indications and timing of this is still uncertain. This review addresses the risk stratification of patients according to thromboembolic risk, indications, timing, and duration, and a practical approach to bridge therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Loss, SurgicalHeparinHumansPerioperative CarePostoperative HemorrhageRisk AssessmentThromboembolismWarfarin

Summary

This review addresses periprocedural bridging anticoagulation, in which heparin temporarily replaces warfarin, covering risk stratification for thromboembolism versus bleeding along with indications, timing, duration of bridge therapy, and a practical management approach.

Context

This review addresses the risk stratification, indications, timing, and practical approaches to periprocedural bridging anticoagulation, which involves substituting heparin for warfarin temporarily. It focuses on balancing the risks of thromboembolism and procedure-related bleeding during invasive procedures. The abstract focuses strictly on conventional medical management with warfarin and heparin. No leeches, hirudin, or related therapies are mentioned or implied in the text.

Citation

Reference (Vancouver style)

Palaniswamy C, Selvaraj DR. Periprocedural bridging anticoagulation: current perspectives. Am J Ther. 2011;18(4):e89-94. doi:10.1097/MJT.0b013e3181d41ed6. PMID: 20228672

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.